
Join to View Full Profile
200 1st St SWRochester, MN 55905
Phone+1 507-284-2511
Dr. McWilliams is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2001 - 2005
- Johns Hopkins UniversityResidency, Internal Medicine, 1997 - 2000
- Georgetown University School of MedicineClass of 1997
Certifications & Licensure
- SD State Medical License Active through 2027
- IA State Medical License 2012 - 2026
- ID State Medical License 2012 - 2026
- IL State Medical License 2012 - 2026
- MT State Medical License 2012 - 2026
- NY State Medical License 2012 - 2026
- MI State Medical License 2012 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Clinical Trials
- Irinotecan, Fluorouracil, Leucovorin, and Oxaliplatin as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2004 Mar 01
- Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery Start of enrollment: 2006 Oct 01
- Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer Start of enrollment: 2007 May 01
- Join now to see all
Publications & Presentations
PubMed
- Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial.Matthew S Block, Garth D Nelson, Jun Chen, Stephen Johnson, Lu Yang
Journal for Immunotherapy of Cancer. 2025-04-15 - ASO Visual Abstract: Molecular KRAS ctDNA Predicts Metastases and Survival in Pancreatic Cancer-A Prospective Cohort Study.Jennifer L Leiting, Roberto Alva-Ruiz, Jennifer A Yonkus, Amro M Abdelrahman, Isaac Lynch
Annals of Surgical Oncology. 2025-04-10 - Fatty acid synthase (FASN) inhibition cooperates with BH3 mimetic drugs to overcome resistance to mitochondrial apoptosis in pancreatic cancer.Travis Vander Steen, Ingrid Espinoza, Cristina Duran, Guillem Casadevall, Eila Serrano-Hervás
Neoplasia. 2025-04-01
Journal Articles
- Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic CancerPashtoon M Kasi, Robert R McWilliams, JAMA
- Female Chromosome X Mosaicism Is Age-Related and Preferentially Affects the Inactivated X ChromosomeChu Chen, J Michael Gaziano, Robert C Kurtz, Anthony M Magliocco, Amy Hutchinson, Robert R McWilliams, Nature
Press Mentions
- Palliative Care for Cancer PatientsNovember 22nd, 2024
- People with Pancreatic Cancer Are Living Longer, Thanks to Improved ApproachesNovember 30th, 2022
- The Topic of CancerJuly 1st, 2022
- Join now to see all
Professional Memberships
- Member
- Member
- Member
External Links
- Mayo Sitehttp://www.mayo.edu/research/faculty/mcwilliams-robert-r-m-d/bio-00027338
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: